Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Reexamination Certificate
2006-11-14
2006-11-14
Schnizer, Richard (Department: 1635)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
C536S023720, C435S235100, C435S320100
Reexamination Certificate
active
07135187
ABSTRACT:
The present invention relates to methods for efficient and reliable construction of adenovirus vectors which contain and express foreign DNA and are useful for gene transfer into mammalian cells, for vaccines and for gene therapy. The invention provides for the growth and purification of adenovirus vectors (helper dependent vectors or HDVs) from which all or most of the viral genes have been removed. The vector system described herein is a new method designed to eliminate helper viruses from the final HDV preparation by cleavage of the helper virus DNA with an endonuclease, alone or in combination with other methods known to limit the level of helper virus contamination of helper dependent vector preparations. The disclosed methods and compositions also provide for regulated control of gene expression.
REFERENCES:
patent: 4510245 (1985-04-01), Cousens et al.
patent: 4797368 (1989-01-01), Carter et al.
patent: 4920209 (1990-04-01), Davis et al.
patent: 4920211 (1990-04-01), Tibbetts et al.
patent: 5474896 (1995-12-01), Dujon et al.
patent: 5670488 (1997-09-01), Gregory et al.
patent: 5849553 (1998-12-01), Anderson et al.
patent: 5882877 (1999-03-01), Gregory et al.
patent: 5919676 (1999-07-01), Graham et al.
patent: 5998205 (1999-12-01), Hallenbeck et al.
patent: 6001557 (1999-12-01), Wilson et al.
patent: 6080569 (2000-06-01), Graham et al.
patent: 6261807 (2001-07-01), Crouzet et al.
patent: 0 919 624 (1999-06-01), None
patent: WO 93/06223 (1993-04-01), None
patent: WO 93/19092 (1993-09-01), None
patent: WO 93/19191 (1993-09-01), None
patent: WO 94/08026 (1994-04-01), None
patent: WO94/12649 (1994-06-01), None
patent: WO95/27071 (1995-12-01), None
patent: WO 96/13597 (1996-05-01), None
patent: WO 96/13598 (1996-05-01), None
patent: WO 96/14408 (1996-05-01), None
patent: WO 96/40955 (1996-12-01), None
patent: WO 97/05255 (1997-02-01), None
patent: WO 97/32481 (1997-09-01), None
patent: WO 98/13510 (1998-04-01), None
patent: WO 99/02647 (1999-02-01), None
patent: WO 99/41400 (1999-08-01), None
patent: WO 99/53085 (1999-10-01), None
patent: WO 99/61638 (1999-12-01), None
Anglana, Mauro and Silvia Bacciietti, “Construction of a Recombinant Adenovirus for Efficient Delivery of the I-Seel Yeast Endonuclease to Human Cells and it's Application in theIn Vivo Cleavageof Chromosomes to Expose New Potential Telomeres,” Nucleic Acids Research (1999) 27 (21) 4276-4181.
Anton, M., and F. L. Graham, 1995, Site-specific recombination mediated by an adenovirus vector expressing the Cre recombinase protein: a molecular switch for control of gene expression, J. Virol. 69: 4600-4606.
Araki, K., J. Araki, J. I. Miyazaki, and P. Vassali, 1995, Site-specific recombination of a transgene in fertilized eggs by transient expression of Cre recombinase. Proc. Nat'l. Acad. Sci. USA 92: 160-164.
Bett, A. J., L. Prevec, and F. L. Graham, 1993, Packaging capacity and stability of human adenovirus type 5 vectors. J. Virol. 67: 5911-5921.
Bett, A. J., W. Haddara, L. Prev, and F. L. Graham, 1994, An efficient and flexible system for construction of adenivorus vectors with insertions or deletions in early region 1 and 3. Proc. Nat'l. Acad. Sci. USA 91:8802-8806.
D'Halluin et al., “Restriction maps of human adenovirus types 2, 5 and 3 for Bell, Clal. Pvul and Sphl”, Gene, 21(1-2):165-169, 1983.
DiSanto, J.P., W. Mueller, D. Guy-Grand, A. Fischer, and K. Rajewsky, 1995, Lymphoid development in mice with a targeted deletion of the interleukin 2 receptor chain, Proc. Nat'l. Acad. Sci. USA 92: 377-381.
Gage, P.J., B. Sauer, M. Levin and J. C. Glorioso. 1992. A cell-free recombination system for site-specific integration of multigenic shuttle plasmids into the herpes simplex virus type 1 genome. J. Virol. 66: 5509-5515.
Genbank Accession No. M73260, 1996.
Graham, F. L. and L. Prevec. 1991. Manipulation of adenovirus vectors. In Murray E.J. (ed.), Methods in Molecular Biology. The Humana Press Inc. Clifton, N.J. vol. 7 (Gene Transfer Expression Protocols): 109-128.
Graham F. L. and L. Prevec. 1992. Adenovirus-based expression vectors and recombinant vaccines. in: Vaccines; New Approaches in Immunological Problems., ed. Ellis, R.W. Butterworth-Heinemann, Boston, MA: 363-390.
Graham F. L., J. Smiley, W. C. Russel and R. Naim. 1977. Characteristics of a human cell line transformed by DNA from human adenovirus type 5., J. Gen. Virol. 36: 59-72.
Gu, H., J. D. Marth, P.C. Orban, H. Mossmann and K. Rajewsky. 1994. Deletion of a DNA polymerase B gene segment in T cells using cell type-specific gene targeting. Science 265: 103-106.
Haj-Ahmad and Graham, “Characterization of an adenovirus type 5 mutant carrying embedded inverted terminal repeats,” Virology, 153:22-34, 1986.
Kangegae Y., et al., “Efficient Gene Activation in Mammalian Cells by Using Recombinant Adenovirus Expressing Site-Specific CRE Recombinase,” Nucleic Acids Research (1995) 23 (19) 3816-3821.
Kilby, N. J., M. R. Snaith, and J. A. H. Murray. 1993. Site-specific recombinases: tools for genome engineering. Trends Genet. 9: 413-421.
Metzger, D., J. Clifford, H. Chiba and P. Chambon. 1995. Conditional site-specific recombination in mammalian cells using a ligand-dependent chimeric Cre protein. Proc. Nat'l. Acad. Sci. USA 92: 6991-6995.
Pichel, J.G., Lakso, and H. Westphal. 1993. Timing of SV40 oncogene activation by site-specific recombination determines subsequent tumor progression during murine lens development. Oncogene 8: 3333-3342.
Sauer, B. 1994. Site-specific recombination: developments and applications. Cur. Opin. Biotech. 5: 521-527.
Sauer, Brian and Nancy Henderson. 1988. Site-specific DNA recombination in mammalian cells by the Cre recombinase of bacteriophage P1. Proc. Nat'l. Acad. Sci. USA 85: 5166-5170nn.
Sauer, B., and N. Henderson. 1990. Targeted insertion of exogenous DNA into the eukaryotic genome by the Cre recombinase. The New Biologist 2: 441-449.
Sauer, B., M. Whealy, A. Robbins and L. Enquist. 1987. Site-specific insertion of DNA into a pseudorabies virus vector. Proc. Nat'l. Adac. Sci. USA 84: 9108-9112.
Smith A. J. H., M. A. DeSousa, B. Kwabi-Addo, A. Heppel-Parton, H. Impey, and P. Rabbits. 1995. A site-directed chromosomal translocation induced in embryonic stem cells by Cre-loxP recombination. Nature Genetics 9: 376-385.
Sternberg, N., B. Sauer, R. Hoess, and K. Abremski. 1986. Bacteriophase P1 cre gene and its regulatory region; Evidence for multiple promotors and for regulation by DNA methylation., J. Mol. Biol. 187: 197-212.
Van Deursen, J., M. Fornerod, B. Van Rees, and G. Grosveld. 1995. Cre-mediated site specific translocation between non-homologous mouse chromosomes. Proc. Nat'l. Acad. Sci. USA 92: 7376-7380.
Mittal, S.K., McDermott, M.R., Johnson, D.C., Prevec, L. and F. L. Graham. 1993. Monitoring foreign gene expression by a human adenovirus-based vector using the firefly luciferase gene as a reporter, Virus Research, 28: 67-90.
Hanke, T., Frank L. Graham, Kenneth L. Rosenthal and David C. Johnson. 1991. Identification of an immunodomimant cytotoxic t-lymphocyte recognition site in glycoprotein B of herpes simplex virus by using recombinant adenovirus vectors and synthetic peptides. 1991. J. of Virology, 65: 1177-1186.
Hearing, Patrick and Shenk, Thomas, 1983, “The Adenovirus Type 5 B1A Transcriptional Control Region Contains A Duplicated Enhancer Element.” Cell:33 695-703.
Graham, F.L., 1987. Growth of 293 cells in suspension culture. J. Gen. Virol. 68: 937-940.
Meganuclease 1-Sec I (Omega-Nuclease) Boehringer Mannheim Catalog (2 pages).
Nicolas, Andrea et al., “Creation and Repair of Specific DNA Double-Strand Breaks In Vivo Following Infection with Adenovirus Vectors Expressing Saccharomyces Cerevisiae HO Endonuclease,” Virology (2000) 266 (1): 211-224.
Quantin, B., Leslie D. Pericaudet, Shahragim Tajbakhsh and Jean-Louis Mandel. 1992. Adenovirus as an expression vector in muscle cells in vivo. Proc. Nat'l. Acad. Scie. 89: 2581-2584.
Rosenfeld, M.A. et al., 1992. In vivo transfer of the human cystic fibrosis transmembrane conductance regula
Graham Frank L.
Ng Philip
Parks Robin
AdVec, Inc.
Beusse Wolter Sanks Mora & Maire, P.A.
Fischer Joseph
Schnizer Richard
LandOfFree
System for production of helper dependent adenovirus vectors... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with System for production of helper dependent adenovirus vectors..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and System for production of helper dependent adenovirus vectors... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3667928